Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026728 · ClinicalTrials.gov registry record
Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 20,169
- Enrollment target
NCT00026728: Completed study, sponsored by National Cancer Institute (NCI).
NCT00026728 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 20,169 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026728 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 20,169 participants
- Enrollment target
Study Summary
This study will investigate patterns of Kaposi's sarcoma herpes virus (KSHV) in the United States and its potential impact on the U.S. population. KSHV is a newly discovered virus that is strongly associated with Kaposi's sarcoma and primary effusion lymphoma. The high prevalence of KS and KSHV among HIV-infected homosexual men suggests sexual contact as a primary mode of transmission. Reports of non-sexual transmission in parts of Africa and the Mediterranean where Kaposi's sarcoma is endemic, and the identification of viral DNA in saliva and other bodily fluids, however, indicate the virus is also transmitted non-sexually. This study will: * Compare the prevalence of KSHV among different demographic groups in the United States * Examine the association between KSHV and high risk behaviors such as drug use (marijuana and cocaine), sexual behavior (age at first sexual intercourse and number of sexual partners), and medical risk factors (herpes simplex virus II, hepatitis B and hepatitis C) * Estimate the prevalence of KSHV in the United States. Data and blood samples for the study will be taken from the NHANES III survey. NHANES is a program of periodic surveys conducted by the Centers for Disease Control and Prevention's National Center for Health Statistics. The survey is designed to provide national estimates of health status for the United States non-institutionalized civilian population by means of household interviews, standardized physical examinations, and blood sample collection and testing. NHANES III-the seventh in a series of national examination studies-was conducted from 1988 to 1994. This study will use the HANES data to identify risks associated with a KSHV-positive blood test in the survey population. The study plans to include all 19,754 participants (67% of the 29,314 participants originally examined) for whom blood samples were collected and remain available.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,169 participants |
| Start Date | 2001-02 |
| Est. Completion | 2005-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026728
The ClinicalTrials.gov registry entry for NCT00026728 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20,169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00026728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026728 about?
NCT00026728 is a clinical study titled "Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States". This study will investigate patterns of Kaposi's sarcoma herpes virus (KSHV) in the United States and its potential impact on the U.S. population. KSHV is a newly discovered virus that is strongly associated with Kaposi's sarcoma and primary effusion lymphoma. The high prevalence of KS and KSHV amon...
What is the current status of trial NCT00026728?
This trial is currently completed. The enrollment target is 20,169 participants. The study started on 2001-02. Estimated completion is 2005-12.
Who is sponsoring clinical trial NCT00026728?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.